Cadila Pharmaceuticals: Russia Operations Status & Business Impact
LeaveRussia detail: Continue Operations
Cadila Pharmaceuticals is an Indian multinational pharmaceutical company based in Ahmedabad. The company's operations focus on manufacturing products ranging from active pharmaceutical intermediates, finished formulations, food supplements, biotechnology products and pharmaceutical machinery.
Decision trail
Decision date 20/04/2023 · Reference ↗
The company continues to work in Russia. Cadila Pharmaceuticals met in 2023 with the Deputy Prime Minister of the Russian Federation and the Minister of International Relations of the Government of Moscow at a powerful bilateral industry round table in New Delhi/ 20224 hsr The Russian Direct Investment Fund (RDIF) and Cadila Pharmaceuticals Ltd., one of the leading private Indian pharmaceutical corporations, have agreed on joint investments in a project to create an innovative pharmaceutical complex and a plant for injectable drugs in Russia.
Local stats (LeaveRussia)
Status history since 2022
- 03/08/2026 — operating · Imported from KSE LeaveRussia
Exposure profile
Get alerts if this company's Russia status changes
7-day Pro trial includes watchlists for companies you track. No credit card. Full exposure maps are on Professional after the trial.
Start 7-day Pro trialGeopolitical context and sanctions impact
Cadila Pharmaceuticals is a Pharma & Healthcare company based in India. Current Russia status in our dataset is operating: continued operations in Russia remain a compliance, reputational and counterparties risk for EU and allied firms. Eastern Europe Impact translates those facts into business consequences — sanctions screening, supply-chain exposure and reconstruction-side opportunity — with transparent confidence labels rather than speculation.
Risk assessment and how to use this profile
Start with the status badge and decision trail, then check possible sanctions matches and recent events mentioning Cadila Pharmaceuticals. A 7-day Pro trial adds watchlists so you are notified if Russia status, designations or linked events change. Full exposure maps (energy, transport, commodities) are on Professional. This page is risk information, not legal or investment advice.
Questions about Cadila Pharmaceuticals
What kind of data does Eastern Europe Impact provide on Cadila Pharmaceuticals?
- Eastern Europe Impact publishes verified intelligence on Cadila Pharmaceuticals's Russia status: current operating posture, sources (including the KSE LeaveRussia project), status history since 2022, sanctions-list matches, and linked events. Each profile is risk information for compliance and due diligence — not legal advice.
How can Eastern Europe Impact data on Cadila Pharmaceuticals help my business?
- Use the Cadila Pharmaceuticals profile to check counterparties, suppliers and customers for Russia exposure, sanctions proximity and recent events before you contract, ship or invest. Watchlists alert you if the status or designations change.
How do we verify the information on Cadila Pharmaceuticals?
- We compile public reporting, company statements and the KSE LeaveRussia dataset, then label uncertainty. Status is not a legal determination — verify against primary filings and counsel before acting. Corrections go to corrections@easterneuropeimpact.com.
How much does Eastern Europe Impact cost?
- The company checker is free. A 7-day Pro trial (no credit card) unlocks live Daily Impact Briefs, full event profiles and watchlists. After the trial, Individual is €19/month; Professional and Business add exposure maps, sanctions entity pages and API access. See /pricing.